



THE INTELLECTUAL PROPERTY LAW ASSOCIATION OF CHICAGO

Proudly Presents The

2018 Creator Of The Year Award

To Dale N. Gerding, M.D.

The IPLAC Creator of the Year Award is given to honor the creative achievements, primarily in the Chicago metropolitan area, that are eligible for patent, copyright, or trademark protection. This year, IPLAC is proud to recognize Dale N. Gerding, M.D. as the winner of the 2018 IPLAC Creator of the Year Award, for his achievements in the area of patents.

Dr. Gerding has the following patents:

- **U.S. Patent and Trademark Office:** Methods and Compositions for Prevention and Treatment of *Clostridium difficile*-Associated Diseases. Filed September 15, 1995, PCT/US96/14868. Patent issued October 21, 2003, U.S. Patent No. 6,635,260.
- **Canadian Intellectual Property Office:** Methods and Compositions for Prevention and Treatment of *Clostridium difficile*-Associated Diseases. Patent issued December 10, 2002, Canadian Patent No. 2,232,001.
- **European Patent Office:** Methods and Compositions for the Prevention and Treatment of *Clostridium difficile*-Associated Diseases. Patent issued November 11, 2005. Patent No. 0952773. Nationalized in 10 countries.

Dale Gerding is a Research Physician at the Edward Hines Jr. VA Hospital and Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois (retired). Prior to his present position, Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine.





He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America and past chair of a committee on the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA. He served as a member of the Board of Directors of IDSA from 2005-2008. He is a Master of the American College of Physicians and the 2013 recipient of the William Middleton Award, the highest research award given by the Department of Veterans Affairs. He is a member of the American Society for Microbiology, and is board certified in Internal Medicine and Infectious Diseases.

His research interests include the epidemiology and prevention of *Clostridium difficile* disease, antimicrobial resistance, and antimicrobial distribution and kinetics. He has been a Merit Review funded research investigator in the VA for over 40 years and is the author of over 400 peer-reviewed journal publications, book chapters, and review articles. He holds patents for the use of non-toxigenic *C. difficile* for the prevention and treatment of this disease. He is a member of the editorial boards of Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Gut Microbes, and Infection Control and Hospital Epidemiology, and is an ad hoc reviewer for numerous other medical journals.

Dr. Gerding was a pioneer in using *Clostridium* strains not producing toxins A and B, and selected by genetic markers and cultured by him, to compete with toxic strains of *Clostridium* that caused severe diarrhea. He was concerned about this serious infection in his work with patients as Chief of Medicine of the Veterans Administration Hospital. He persisted in his work regarding his proposed treatment, and sought patents when many discounted the possibility of success. He formed a company, ViroPharma, and licensed his patents for commercialization.